ClinicalTrials.gg
RecruitingNCT07847983HER-HFUpdated Oct 21, 2026

Heart Failure in Women: Epidemiological and Prognostic Insights

An observational study in Heart Failure, sponsored by Carolina Ortiz Cortes. Recruiting at 24 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Carolina Ortiz Cortes · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 21, 2026Eligibility revisedPrimary outcomes revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
430
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.

Planned enrollment
45th of 78
430 · median 500
Started
2026
with 21 others
Observational
78 of 342
18 open now
Primary completion
2028-03
later than 66 of 98 live
Registered
342nd of 342
by date

Among the 342 studies in Heart Failure with a site in Spain, this one is the 45th largest by planned enrollment of the 78 observational ones that give a count, is one of 22 that started in 2026, is one of 78 observational ones, reaches primary completion later than 66 of the 98 other live ones, and was the 342nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:

70 more — sign in →

All 76 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Heart Failure with a site in Spain, or all of them as a file.
02

Study summary

Heart failure (HF) is a leading cause of hospital admission in older adults and women account for more than half of these admissions, yet they remain under-represented in prospective HF cohorts. Risk factors specific to women, such as complications of pregnancy and the timing of menopause, are seldom recorded in HF registries, and treatment is usually described by drug class rather than by the dose actually achieved.

HER-HF is a national, prospective, multicenter observational cohort study that enrolls women aged 18 years or older admitted to hospital for a first episode of HF, irrespective of left ventricular ejection fraction, at 24 Spanish hospitals with a dedicated heart failure unit. Recruitment is consecutive and all-comers. Participants are enrolled at discharge from the index admission or at the first heart failure unit visit within 15 days, and all baseline data refer to the index hospitalization. Participants are followed for 12 months, with visits at 3, 6 and 12 months.

The primary objective is descriptive: to characterize the epidemiological, clinical, diagnostic, therapeutic and prognostic profile of women with de novo HF, from the index admission through 12 months. Secondary objectives are: (1) to evaluate the association of sex-specific risk factors with the clinical profile, the type of HF (ejection fraction phenotype and etiology), the management received and 12-month prognosis, adjusted for traditional risk factors; (2) to examine the association of individual social determinants (household income, number of people in the household and educational attainment) with the type of HF, age at onset, management and outcome; and (3) to compare the cohort with a contemporary cohort of men with newly diagnosed HF (TIDY-HF registry) to identify sex-specific differences. The principal prognostic endpoint is the composite of all-cause death or HF decompensation (hospitalization for HF, or an unplanned emergency department or day-hospital visit for HF) within 12 months.

Read the detailed description

Data are collected in a centralized, encrypted electronic case report form. Baseline variables include demographics, cardiovascular risk factors and comorbidity, previous cardiological history and prior medication; sex-specific risk factors recorded in the clinical history of the index admission (number of pregnancies and deliveries; preeclampsia, eclampsia or HELLP syndrome; gestational hypertension and gestational diabetes; preterm delivery; intrauterine growth restriction or small-for-gestational-age newborn; peripartum cardiomyopathy; recurrent pregnancy loss; menopausal status and age at menopause; hormone replacement therapy; polycystic ovary syndrome; and endometriosis); previous cardiotoxic cancer therapy (chemotherapy or radiotherapy), recorded with the oncological history as a female-predominant risk factor; individual social determinants (net monthly household income, number of people in the household and educational attainment); clinical features of the index episode; laboratory, electrocardiographic and echocardiographic data; cardiac magnetic resonance, coronary angiography and other investigations when performed; treatment at discharge by drug class and dose band, with adverse effects and whether these led to dose reduction or withdrawal; devices and cardiac interventions; and the Barthel index, the Pfeiffer questionnaire, the five-item Geriatric Depression Scale and the 12-item Kansas City Cardiomyopathy Questionnaire.

At each follow-up visit (3, 6 and 12 months) the following are recorded: functional class, physical examination for residual congestion, weight and blood pressure, laboratory tests and electrocardiogram, current treatment with doses, tolerability and adverse effects, emergency department attendances and day-hospital treatments for heart failure, hospitalizations for heart failure, for other cardiovascular causes and for non-cardiovascular causes, referral to cardiac rehabilitation and referral for advanced therapies. Echocardiography is performed at the index admission, once during follow-up at the 3- or 6-month visit, and again by the 12-month visit. Vital status and cause of death are recorded throughout; clinical events are ascertained by the site investigator from the clinical and regional electronic health records, without central adjudication. Functional and health-status scales are repeated at 12 months.

To document and control selection bias, each site declares a fixed screening frame in advance and maintains a screening log recording the number of women screened, the number confirmed eligible, the number enrolled, and the number of eligible women not enrolled with the reason. Participation rates will be reported by site.

The sample size was calculated for descriptive precision: with the most conservative proportion (p = 0.50), 95% confidence and an absolute precision of 5%, 385 evaluable women are required; allowing for 10% loss to follow-up over 12 months, 430 women will be recruited. Results will be presented overall and by ejection fraction phenotype according to the 2026 European Society of Cardiology definitions (reduced, below 50%; preserved, 50% or higher; also reporting 40% or lower and 41-49% separately) and by age (under 75 or 75 years and older). Time to the composite endpoint will be analyzed with Kaplan-Meier curves and Cox models with standard errors clustered by center; all secondary analyses are exploratory. The comparison with the men of the TIDY-HF registry will include all women for clinical profile and investigations, and women with an ejection fraction of 40% or lower, the population enrolled in TIDY-HF, for the class and dose of foundational medical therapy, with adjustment for age.

03

Conditions studied

  • Heart Failure

Keywords

  • Heart failure
  • Women
  • Sex characteristics
  • Registry
  • Pregnancy complications
  • Menopause
  • Prognosis
  • Social determinants of health
  • Cardiotoxicity
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women aged 18 years or older admitted to hospital with a first episode of heart failure at 24 participating Spanish centers, all of which have a dedicated heart failure unit. Recruitment is consecutive and all-comers: every woman meeting the criteria during the recruitment period is offered participation, and discretionary selection by investigators is not permitted. Each center declares a fixed screening frame in advance and keeps a screening log of women screened, women confirmed eligible, women enrolled, and eligible women not enrolled with the reason. Concurrent participation in an interventional trial is not an exclusion criterion but is recorded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years or older.
  • Hospital admission with a first episode of heart failure confirmed by the treating team according to current clinical practice guidelines, irrespective of .
  • Written given by the participant after verbal and written information.

Exclusion criteria

Exclusion Criteria:

  • Total functional dependence, defined as a Barthel index score of 20 or less (0-100 version).
  • Moderate-to-severe cognitive impairment, defined as 5 or more errors on the Pfeiffer questionnaire, adjusted for educational attainment.
  • Severe frailty, defined as a Clinical Frailty Scale score of 6 or more.
  • Terminal illness unrelated to heart failure with an expected survival of less than 6 months according to clinical judgment.
  • Inability to complete clinical follow-up or subsequent contact (for example, no contact details available, or transfer to a center outside the network).
  • Any previous diagnosis of heart failure.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
430 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Women with a first hospitalization for heart failure

    Women aged 18 years or older admitted to hospital with a first episode of heart failure confirmed by the treating team according to current clinical practice guidelines, irrespective of left ventricular ejection fraction, and with no previous diagnosis of heart failure. Participants are enrolled consecutively (all-comers) at discharge from the index admission or at the first heart failure unit visit within 15 days of discharge, and are followed for 12 months with visits at 3, 6 and 12 months. No intervention is assigned by the protocol; all diagnostic and therapeutic decisions are made by the treating clinician as part of routine care.

06

What researchers measure

Primary outcomes

  1. Composite of all-cause death or heart failure decompensation

    Time from enrollment to the earlier of death from any cause or heart failure decompensation, defined as hospitalization with heart failure as the principal reason for admission, or an unplanned emergency department or day-hospital visit for worsening heart failure. Events are ascertained by the site investigator from the clinical and regional electronic health records at each scheduled visit; there is no central adjudication.

    Time frame: 12 months from enrollment

Secondary outcomes

  1. All-cause mortality

    Proportion of participants who die from any cause during follow-up, with date and cause of death recorded and classified as cardiovascular or non-cardiovascular.

    Time frame: 12 months from enrollment

  2. Rehospitalization for heart failure

    Number of participants with at least one hospital admission with heart failure as the principal reason for admission, and the total number of such admissions.

    Time frame: 12 months from enrollment

  3. Prevalence of sex-specific and female-predominant risk factors

    Proportion of participants with each recorded sex-specific risk factor: number of pregnancies and deliveries, preeclampsia, eclampsia or HELLP syndrome, gestational hypertension, gestational diabetes, preterm delivery before 37 weeks, intrauterine growth restriction or small-for-gestational-age newborn, peripartum cardiomyopathy, recurrent pregnancy loss, premature menopause before 40 years, hormone replacement therapy, polycystic ovary syndrome and endometriosis; and proportion with previous cardiotoxic cancer therapy (chemotherapy or radiotherapy), recorded as a female-predominant risk factor.

    Time frame: Baseline (index hospitalization)

  4. Distribution of left ventricular ejection fraction phenotype

    Proportion of participants in each left ventricular ejection fraction category measured by transthoracic echocardiography during the index hospitalization: reduced (below 50%) or preserved (50% or higher) according to the 2026 European Society of Cardiology definitions, also reporting 40% or lower and 41-49% separately.

    Time frame: Baseline (index hospitalization)

  5. Use and achieved dose of disease-modifying heart failure therapy

    Proportion of participants receiving each class of disease-modifying therapy (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, finerenone, sodium-glucose cotransporter 2 inhibitors, vericiguat, ivabradine, diuretics and potassium binders) and the dose band achieved for each.

    Time frame: Discharge from the index hospitalization and 3, 6 and 12 months

  6. Adverse effects limiting disease-modifying therapy

    Proportion of participants with hypotension, bradycardia, conduction disturbance, worsening renal function, hyperkalemia or other adverse effects attributed to disease-modifying therapy, and whether these led to dose reduction or withdrawal of the drug.

    Time frame: 12 months from enrollment

  7. Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score

    Change from baseline in the overall summary score of the 12-item Kansas City Cardiomyopathy Questionnaire. The score ranges from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline and 12 months

  8. Functional and cognitive status scales

    Barthel index (0 to 100, higher scores indicate greater independence), Pfeiffer Short Portable Mental Status Questionnaire (0 to 10 errors, higher scores indicate greater cognitive impairment) and the five-item Geriatric Depression Scale (0 to 5, higher scores indicate more depressive symptoms).

    Time frame: Baseline and 12 months

  9. Emergency department attendances and day-hospital treatments for heart failure

    Number of participants attending the emergency department or receiving intravenous diuretic treatment in a day-hospital setting for worsening heart failure, and the number of such episodes.

    Time frame: 12 months from enrollment

  10. Referral to cardiac rehabilitation and to advanced heart failure therapies

    Proportion of participants referred to a cardiac rehabilitation program and proportion referred for evaluation for heart transplantation or ventricular assist device.

    Time frame: 12 months from enrollment

  11. Hospitalization for cardiovascular causes other than heart failure and for non-cardiovascular causes

    Number of participants admitted to hospital for a cardiovascular cause other than heart failure, and number admitted for a non-cardiovascular cause, with the number of such admissions.

    Time frame: 12 months from enrollment

  12. Individual social determinants

    Distribution of net monthly household income (euros), number of people in the household (including the participant) and educational attainment, recorded in six categories: unable to read or write or incomplete primary education; complete primary education; lower secondary education; upper secondary education or vocational training; university education; unknown or declined to answer. These variables are analyzed as exposures against the type of heart failure, age at onset, management and outcome.

    Time frame: Baseline (index hospitalization)

07

Study locations

24 of 24 sites recruiting
  • Complexo Hospitalario Universitario A Coruna
    A Coruña, A Coruna, Spain
    Recruiting
    • Daniel Enriquez Vazquez · Principal investigator
  • Hospital Clinico Universitario de Santiago de Compostela
    Santiago de Compostela, A Coruna, Spain
    Recruiting
    • Ines Gomez Otero · Principal investigator
  • Hospital Universitario de Badajoz
    Badajoz, Badajoz, Spain
    Recruiting
    • Alejandra Vaello Panos · Principal investigator
  • Hospital Universitario de Burgos
    Burgos, Burgos, Spain
    Recruiting
    • Angel Perez Rivera · Principal investigator
  • Hospital Universitario de Caceres
    Cáceres, Caceres, Spain
    Recruiting
    • Benjamin Roque Rodriguez · Principal investigator
  • Hospital Universitario Puerta del Mar
    Cadiz, Cadiz, Spain
    Recruiting
    • Cesar Jimenez-Mendez · Principal investigator
  • Hospital Universitario Donostia
    Donostia / San Sebastian, Gipuzkoa, Spain
    Recruiting
    • Cristina Goena Vives · Principal investigator
  • Hospital Universitari de Girona Doctor Josep Trueta
    Girona, Girona, Spain
    Recruiting
    • Paula Fluvia · Principal investigator
  • Hospital Universitario Virgen de las Nieves
    Granada, Granada, Spain
    Recruiting
    • Silvia Lopez Fernandez · Principal investigator
  • Hospital San Juan de la Cruz
    Úbeda, Jaen, Spain
    Recruiting
    • Juan Luis Bonilla Palomas · Principal investigator
  • Hospital Universitario de Gran Canaria Doctor Negrin
    Las Palmas de Gran Canaria, Las Palmas, Spain
    Recruiting
    • Antonio Garcia Quintana · Principal investigator
  • Complejo Asistencial Universitario de Leon
    León, Leon, Spain
    Recruiting
    • Miguel Rodriguez Santamarta · Principal investigator
  • Hospital Universitario Fundacion Alcorcon
    Alcorcón, Madrid 28922, Spain
    Recruiting
    • Carolina Ortiz Cortes · Principal investigator
  • Hospital Universitario HM Monteprincipe
    Boadilla del Monte, Madrid, Spain
    Recruiting
    • Leticia Fernandez-Friera · Principal investigator
  • Hospital Universitario Severo Ochoa
    Leganés, Madrid, Spain
    Recruiting
    • Alberto Esteban Fernandez · Principal investigator
  • Hospital Central de la Defensa Gomez Ulla
    Madrid, Madrid, Spain
    Recruiting
    • Juan Gorriz · Principal investigator
  • Hospital Universitario de La Princesa
    Madrid, Madrid, Spain
    Recruiting
    • Pablo Diez-Villanueva · Principal investigator
  • Hospital Universitario Infanta Leonor
    Madrid, Madrid, Spain
    Recruiting
    • Cristina Beltran Herrera · Principal investigator
  • Hospital Universitario Ramon y Cajal
    Madrid, Madrid, Spain
    Recruiting
    • Jesus Alvarez Garcia · Principal investigator
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid, Spain
    Recruiting
    • Marta Cobos Marcos · Principal investigator
  • Hospital Universitario Central de Asturias
    Oviedo, Principality of Asturias, Spain
    Recruiting
    • Beatriz Diaz Molina · Principal investigator
  • Hospital Universitario de Toledo
    Toledo, Toledo, Spain
    Recruiting
    • Natalia Navarro Pelegrini · Principal investigator
  • Hospital Universitario Doctor Peset
    Valencia, Valencia, Spain
    Recruiting
    • Maria Amparo Valls Serral · Principal investigator
  • Hospital Universitario Rio Hortega
    Valladolid, Valladolid, Spain
    Recruiting
    • Ramon Andion Ogando · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available. Requests for scientific collaboration should be addressed to the coordinating investigator and will be considered by the steering committee of the registry.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 18 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Jun 30, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 15 sites removed
Show 15 added (15 Spain)
  • Complexo Hospitalario Universitario A Coruna · A Coruña, Spain
  • Hospital Universitario de Badajoz · Badajoz, Spain
  • Hospital Universitario de Burgos · Burgos, Spain
  • Hospital Universitario de Caceres · Cáceres, Spain
  • Hospital Universitario Puerta del Mar · Cadiz, Spain
  • Hospital Universitari de Girona Doctor Josep Trueta · Girona, Spain
  • Hospital Universitario Virgen de las Nieves · Granada, Spain
  • Complejo Asistencial Universitario de Leon · León, Spain
  • Hospital Central de la Defensa Gomez Ulla · Madrid, Spain
  • Hospital Universitario de La Princesa · Madrid, Spain
  • Hospital Universitario Infanta Leonor · Madrid, Spain
  • Hospital Universitario Ramon y Cajal · Madrid, Spain
  • Hospital Universitario de Toledo · Toledo, Spain
  • Hospital Universitario Doctor Peset · Valencia, Spain
  • Hospital Universitario Rio Hortega · Valladolid, Spain
Show 15 removed
  • Complexo Hospitalario Universitario A Coruna · A Coruña, Spain
  • Hospital Universitario de Badajoz · Badajoz, Spain
  • Hospital Universitario de Burgos · Burgos, Spain
  • Hospital Universitario Puerta del Mar · Cadiz, Spain
  • Hospital Universitario de Caceres · Cáceres, Spain
  • Hospital Universitari de Girona Doctor Josep Trueta · Girona, Spain
  • Hospital Universitario Virgen de las Nieves · Granada, Spain
  • Complejo Asistencial Universitario de Leon · León, Spain
  • Hospital Central de la Defensa Gomez Ulla · Madrid, Spain
  • Hospital Universitario de La Princesa · Madrid, Spain
  • Hospital Universitario Infanta Leonor · Madrid, Spain
  • Hospital Universitario Ramon y Cajal · Madrid, Spain
  • Hospital Universitario de Toledo · Toledo, Spain
  • Hospital Universitario Doctor Peset · Valencia, Spain
  • Hospital Universitario Rio Hortega · Valladolid, Spain
Oct 21, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedWritten informed consent given by the participant, or by her legal representative when decision-making capacity is preserved despite mild impairment, after verbal and written information.
Exclusion criteria
  • EditedTerminal illness unrelated to heart failure with an expected survival of less than 6 months according to clinical judgementjudgment.
  • EditedInability to complete clinical follow-up or subsequent contact (for example, no contact details available, or transfer to a centrecenter outside the network).
Oct 21, 2026
Interventions
Arm changed Women with a first hospitalisation for heart failure→Women with a first hospitalization for heart failure
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedComposite of all-cause death or first rehospitalisation for heart failure decompensationTime frame: 12 months from enrolment → 12 months from enrollment
Oct 21, 2026
Secondary outcomes
3 edited, 6 time frame changed, 1 added, 3 description edited
What changed in the outcomes
  • EditedRehospitalisationRehospitalization for heart failureTime frame: 12 months from enrolment → 12 months from enrollment
  • EditedPrevalence of sex-specific reproductive exposuresand female-predominant risk factorsTime frame: Baseline (index hospitalisation) → Baseline (index hospitalization)
  • EditedHospitalisationHospitalization for cardiovascular causes other than heart failure and for non-cardiovascular causesTime frame: 12 months from enrolment → 12 months from enrollment
  • AddedIndividual social determinantsTime frame: Baseline (index hospitalization)
  • Time frameAll-cause mortality12 months from enrolment → 12 months from enrollment
  • Time frameDistribution of left ventricular ejection fraction phenotypeBaseline (index hospitalisation) → Baseline (index hospitalization)
  • Time frameUse and achieved dose of disease-modifying heart failure therapyDischarge from the index hospitalisation and 3, 6 and 12 months → Discharge from the index hospitalization and 3, 6 and 12 months
  • Time frameAdverse effects limiting disease-modifying therapy12 months from enrolment → 12 months from enrollment
  • Time frameEmergency department attendances and day-hospital treatments for heart failure12 months from enrolment → 12 months from enrollment
  • Time frameReferral to cardiac rehabilitation and to advanced heart failure therapies12 months from enrolment → 12 months from enrollment
  • DescriptionAdverse effects limiting disease-modifying therapy: how it is measured was reworded
  • DescriptionDistribution of left ventricular ejection fraction phenotype: how it is measured was reworded
  • DescriptionReferral to cardiac rehabilitation and to advanced heart failure therapies: how it is measured was reworded
Oct 21, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Hospital San Juan de la Cruz · Úbeda, SpainContact person changed (no phone or email listed)
  • Hospital Universitario HM Monteprincipe · Boadilla del Monte, SpainContact person changed (no phone or email listed)
Oct 21, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Oct 21, 2026
    15 sites added, 15 sites removed
    Show 15 added (15 Spain)
    • Complexo Hospitalario Universitario A Coruna · A Coruña, Spain
    • Hospital Universitario de Badajoz · Badajoz, Spain
    • Hospital Universitario de Burgos · Burgos, Spain
    • Hospital Universitario de Caceres · Cáceres, Spain
    • Hospital Universitario Puerta del Mar · Cadiz, Spain
    • Hospital Universitari de Girona Doctor Josep Trueta · Girona, Spain
    • Hospital Universitario Virgen de las Nieves · Granada, Spain
    • Complejo Asistencial Universitario de Leon · León, Spain
    • Hospital Central de la Defensa Gomez Ulla · Madrid, Spain
    • Hospital Universitario de La Princesa · Madrid, Spain
    • Hospital Universitario Infanta Leonor · Madrid, Spain
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
    • Hospital Universitario de Toledo · Toledo, Spain
    • Hospital Universitario Doctor Peset · Valencia, Spain
    • Hospital Universitario Rio Hortega · Valladolid, Spain
    Show 15 removed
    • Complexo Hospitalario Universitario A Coruna · A Coruña, Spain
    • Hospital Universitario de Badajoz · Badajoz, Spain
    • Hospital Universitario de Burgos · Burgos, Spain
    • Hospital Universitario Puerta del Mar · Cadiz, Spain
    • Hospital Universitario de Caceres · Cáceres, Spain
    • Hospital Universitari de Girona Doctor Josep Trueta · Girona, Spain
    • Hospital Universitario Virgen de las Nieves · Granada, Spain
    • Complejo Asistencial Universitario de Leon · León, Spain
    • Hospital Central de la Defensa Gomez Ulla · Madrid, Spain
    • Hospital Universitario de La Princesa · Madrid, Spain
    • Hospital Universitario Infanta Leonor · Madrid, Spain
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
    • Hospital Universitario de Toledo · Toledo, Spain
    • Hospital Universitario Doctor Peset · Valencia, Spain
    • Hospital Universitario Rio Hortega · Valladolid, Spain
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedWritten informed consent given by the participant, or by her legal representative when decision-making capacity is preserved despite mild impairment, after verbal and written information.
    Exclusion criteria
    • EditedTerminal illness unrelated to heart failure with an expected survival of less than 6 months according to clinical judgementjudgment.
    • EditedInability to complete clinical follow-up or subsequent contact (for example, no contact details available, or transfer to a centrecenter outside the network).
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedComposite of all-cause death or first rehospitalisation for heart failure decompensationTime frame: 12 months from enrolment → 12 months from enrollment
    Secondary outcomes 3 edited, 6 time frame changed, 1 added, 3 description edited
    What changed in the outcomes
    • EditedRehospitalisationRehospitalization for heart failureTime frame: 12 months from enrolment → 12 months from enrollment
    • EditedPrevalence of sex-specific reproductive exposuresand female-predominant risk factorsTime frame: Baseline (index hospitalisation) → Baseline (index hospitalization)
    • EditedHospitalisationHospitalization for cardiovascular causes other than heart failure and for non-cardiovascular causesTime frame: 12 months from enrolment → 12 months from enrollment
    • AddedIndividual social determinantsTime frame: Baseline (index hospitalization)
    • Time frameAll-cause mortality12 months from enrolment → 12 months from enrollment
    • Time frameDistribution of left ventricular ejection fraction phenotypeBaseline (index hospitalisation) → Baseline (index hospitalization)
    • Time frameUse and achieved dose of disease-modifying heart failure therapyDischarge from the index hospitalisation and 3, 6 and 12 months → Discharge from the index hospitalization and 3, 6 and 12 months
    • Time frameAdverse effects limiting disease-modifying therapy12 months from enrolment → 12 months from enrollment
    • Time frameEmergency department attendances and day-hospital treatments for heart failure12 months from enrolment → 12 months from enrollment
    • Time frameReferral to cardiac rehabilitation and to advanced heart failure therapies12 months from enrolment → 12 months from enrollment
    • DescriptionAdverse effects limiting disease-modifying therapy: how it is measured was reworded
    • DescriptionDistribution of left ventricular ejection fraction phenotype: how it is measured was reworded
    • DescriptionReferral to cardiac rehabilitation and to advanced heart failure therapies: how it is measured was reworded
    Interventions Arm changed Women with a first hospitalisation for heart failure→Women with a first hospitalization for heart failure
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Hospital San Juan de la Cruz · Úbeda, SpainContact person changed (no phone or email listed)
    • Hospital Universitario HM Monteprincipe · Boadilla del Monte, SpainContact person changed (no phone or email listed)
    + 5 other changes: index terms, identifiers, verification date, description and conditions
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847983
Lead sponsor
Carolina Ortiz Cortes
Responsible party
Carolina Ortiz Cortes (National Coordinating Investigator, Department of Cardiology, Hospital Universitario Fundacion Alcorcon, Universidad de Extremadura) — Sponsor-investigator
First posted
Sep 29, 2026
Start date
Sep 17, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Carolina Ortiz Cortes, MD
Contact
carol.ortizcortes@secardiologia.es
+34 91 621 94 00
Carolina Ortiz Cortes, MD
principal investigator · Hospital Universitario Fundacion Alcorcon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion